Kineret (correction)
Executive Summary
Kineret (anakinra) was approved for slowing the progression of structural damage in rheumatoid arthritis Aug. 22, not Aug. 25 (1"The Pink Sheet" Sept 1, 2003, In Brief)...
You may also be interested in...
Kineret adds RA structural damage indication
Amgen Kineret (anakinra) indication expanded to include slowing the progression of structural damage in moderately to severely active rheumatoid arthritis following FDA approval Aug. 22. The intravenous drug was originally approved in 2001 for the signs and symptoms of RA...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.